Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (02315.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 62.65

From 52W high−12.81%

Volume3.84M

Market capHKD 24.50B

P/E (TTM)61.6x

P/S (TTM)12.3x

Div yield—

Key dataSep 18, 2026

Open

HKD 62.65

From 52W high

−12.81%

Volume

3.84M

Market cap

HKD 24.50B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

35.5x

P/E (TTM)

61.6x

RSI (14)

52.7

MomentumView details →

1D Return

+0.25%

YTD Return

+73.51%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

61.6x

EV/EBITDA

35.5x

EV/Sales

12.2x

P/S (TTM)

12.3x

P/B (TTM)

8.7x

ProfitabilityView details →

Gross Margin

77.06%

Net Margin

21.54%

EBITDA Margin

34.41%

ROE (TTM)

15.13%

ROA (TTM)

10.06%

Asset Turnover

0.46x

GrowthView details →

Revenue YoY

+42.77%

EPS YoY

+149.12%

FCF YoY

−59.32%

Revenue CAGR 3Y

+37.20%

EPS CAGR 3Y

+410.08%

EBITDA YoY

+52.96%

MomentumView details →

1D Return

+0.25%

YTD Return

+73.51%

1Y Return

+122.73%

RSI (14)

52.7

vs 50D SMA

+4.53%

vs 200D SMA

+24.61%

Capital & dividendView details →

Debt/Equity

0.36x

Current Ratio

3.30x

Quick Ratio

2.86x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

HKD 0.62

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

2.89B

Net Income (TTM)

498.51M

Op. CF (TTM)

796.17M

Next earningsMar 31, 2027 →

Latest newsMore news →

Biocytogen's board approved adjustments to its IPO fundraising project "Drug Early R&D Service Platform Construction Project", raising the total investment from 454 million yuan to 462 million yuan, with the additional 8 million yuan funded by its own funds while the raised funds invested remain unchanged at 454 million yuan, and changing the payment method for the remaining construction costs to a leasing model, with the project's expected usable date extended to June 30, 2027.4d ago

Biocytogen Pharmaceuticals announced its interim results for the six months ended June 30, 2026, reporting net profit of 241 million RMB, up 402.3% year-on-year, and revenue of 941 million RMB, up 51.6% year-on-year.24d ago

Similar companies

特宝生物688278.SH BioNTech SEBNTX Incyte CorporationINCY 天坛生物600161.SH InnoCare Pharma Limited09969.HK Royalty Pharma plcRPRX Find similar companies →

Latest newsMore news →

Biocytogen's board approved adjustments to its IPO fundraising project "Drug Early R&D Service Platform Construction Project", raising the total investment from 454 million yuan to 462 million yuan, with the additional 8 million yuan funded by its own funds while the raised funds invested remain unchanged at 454 million yuan, and changing the payment method for the remaining construction costs to a leasing model, with the project's expected usable date extended to June 30, 2027.4d ago Biocytogen Pharmaceuticals announced its interim results for the six months ended June 30, 2026, reporting net profit of 241 million RMB, up 402.3% year-on-year, and revenue of 941 million RMB, up 51.6% year-on-year.24d ago Biocytogen expects net profit attributable to parent for the first half of 2026 to be 236.0944 million to 246.0944 million yuan, up 391.87% to 412.71% year-on-year.45d ago